Innovative, first-in-class medicines are being adopted twice as fast as they were a decade ago, while leadership positions are eroding faster still. Any initial advantage may therefore prove short-lived as competitors enter the market, treatment pathways evolve, and stakeholder expectations shift.
For launch teams, this leaves a narrowing window in which to influence uptake. Choices made before approval and during the earliest stages of commercialization now carry more weight, while mistakes become harder and more expensive to correct.
Launch readiness increasingly depends on knowing the key leverage points in the adoption curve that can cause uptake to accelerate, plateau, or stall.
Commercial execution tells only part of the story
Pharmaceutical companies have devoted considerable resources to launch excellence, strengthening governance, cross-functional planning, and execution. These disciplines remain vital, but they cannot account for every force shaping uptake in a more complex market.
What really changes the uptake curve?
Launch teams have often assumed that the core drivers of uptake are broadly transferable across products and markets.
Prescient’s latest research, based on hundreds of launches over 5+ years and across 30+ countries, has identified critical factors that shape launch uptake curves. After accounting for market access restrictions, the research indicates that launch archetype and therapy area have a substantial bearing on uptake. By comparison, differences in promotional activity alone appear to have far less influence.
This does not diminish the importance of promotion or price; both should be considered alongside the conditions that allow adoption to occur. The more pressing question is not simply how much activity surrounds a launch, but which factors can alter the launch trajectory.
Different therapy areas inherently have different leverage points
In rare disease, patients may remain undiagnosed or pass through the healthcare system without reaching the appropriate specialist. Success hinges on building the system that finds them: reducing diagnostic delay, improving referral infrastructure, activating expert centers, and working with patient communities to support screening and diagnosis.
Biomarker-driven oncology presents another challenge. Launching the marker can matter as much as launching the medicine. Testing must be embedded at the time of diagnosis, results must reach physicians before the first-line treatment decision, and pathology services must connect eligible patients to treatment without unnecessary delay.
In cardiovascular disease, volume economics are critical, with robust clinical outcome data serving as the entry point rather than the deciding factor. Large eligible populations, clinical inertia, and inconsistent identification make population case finding, electronic health record risk flags, guideline inclusion, broad access, and frictionless initiation decisive.
Other therapeutic settings bring their own demands: national recommendations can create the market in vaccines; evidence development is central in immunology; and patient activation is a key determinant in dermatology.
Precision strategies: access × therapy area × launch archetype
As Maxine Smith explores in One-Size-Fits-All Pharma Launches Are Over, understanding how leverage points vary by therapy area, launch archetype, and access conditions enables teams to develop precision strategies that drive uptake. Relevant archetype parameters include whether the medicine is entering a new or established market, whether it is first in class or a fast follower, and the level of competition and differentiation.
So what does this mean in practice? In cardiovascular disease, clinical guidelines gate volume for a first-in-class medicine with no direct competition. Clinical development should therefore account for the endpoints that guidelines will demand at launch, rather than focusing solely on those required for regulatory approval.
For a fast follower, speed is the game, with breadth of coverage beating depth of message. In an established market where meaningful differentiation remains possible, launches should prioritize patients ready to switch to a new therapy. Excellence in population case finding, supported by electronic health record risk flags and audit-and-feedback interventions, can help overcome clinical inertia.
In an established market with high levels of competition and limited differentiation, this analysis suggests clinical messaging alone will not move the needle. Success may instead depend on frictionless initiation, with rapid reimbursement at the local level enabling a one-step start and seamless execution.
Immunology provides another example of how therapy area and launch archetype interaction shapes the moments that matter most during the launch. Although sustained uptake depends on a continuous evidence advantage, the precise leverage point varies by launch archetype. This could involve defining the response threshold against which a new class will be judged, establishing registry evidence, developing new positioning evidence, or strengthening post-failure positioning and persistence data.
Understanding specific launch levers will set leaders apart
Launch excellence remains critical. Strong governance, cross-functional alignment, forecasting, and execution provide the foundation for successful commercialization. But that foundation is not enough.
Future outperformance rests on understanding how therapy area, launch archetype, and access conditions interact, identifying the moments that will exert the greatest influence, and adopting precision strategies in response.
As launch windows become more compressed, organizations have less room to rely on activity as a proxy for impact. The advantage will belong to those who know where to focus investment, where they can create change, and how they will sustain it.
Join us in Boston
We will be presenting more on this research at the Pharma Launch Excellence Summit in Boston, 30 September – 1 October – we would love to see you there. Otherwise, please get in touch if you would like to hear more (mdagless@prescienthg.com).
The Prescient Launch Excellence Report 2026
